TF you even talking about? Lovaza's entire schtick was 15 years ago everyone believed lower trigs = cvd benefit. Dr's Rx'd billions in sales based on that belief. Trigs was an accepted biomarker for cvd at the time.
The Anchor label wasn't going to be a CVD label. The phase 3 was only lower Trigs and that was the label. Still a surrogate indicator for CVD benefit. Vascepa was Lovaza's refinement, a brand replacement for Lovaza that was going generic. Brought to the US by the same crew copying Mochida IP in both cases. The sale pitch was lowers trigs like Lovaza but doenst impact ldl-c like Lovaza so it's much better. It had a target market 10x the size of Lovaza that was selling >$1B a year. It was going to be huge. Reduce It was only run because FDA demanded it be enrolled before granting the Anchor label because they didnt like Jelis focused on high fish Japanese diets.
FDA changed their position on trigs as a surrogate for CVD, pulled the SPA, and that killed the Anchor label and ultimately Amarin. All Amarin had left was Reduce It, so they finished it out and tried to market that as an indication.
Market Data 
Markets 
AI
